Ignite Creation Date:
2024-05-06 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 2:18 PM
Study NCT ID:
NCT05133050
Status:
NOT_YET_RECRUITING
Last Update Posted:
2021-11-24
First Post:
2021-10-27
Brief Title:
Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3COL4A4COL4A5 Variants
Sponsor:
Xinhua Hospital Shanghai Jiao Tong University School of Medicine
Organization:
Xinhua Hospital Shanghai Jiao Tong University School of Medicine
Study Overview
Official Title:
Safety and Efficacy of Early Angiotensin-converting Enzyme Inhibition in Patients With Alport Syndrome Carrying Pathogenic Heterozygous COL4A3COL4A4 or COL4A5 Mutations
Status:
NOT_YET_RECRUITING
Status Verified Date:
2021-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Alport syndrome AS is the second most common monogenic cause of end-stage renal failure ESRF AS is caused by variants in the COL4A3 COL4A4 and COL4A5 genes which encode for the a3 a4 and a5 chains of type IV collagen This trial is a prospective randomized controlled and multicenter trial Mainly to assess the safety and efficacy of ramipril in Alport syndrome patients with variants of COL4A3COL4A4COL4A5
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None